Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
DNA$12.37+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $561,572 | $944,073 |
| Accounts receivable, net | 21,857 | 17,157 |
| Accounts receivable - related parties | 586 | 742 |
| Prepaid expenses and other current assets | 18,729 | 39,777 |
| Total current assets | 602,744 | 1,001,749 |
| Property, plant and equipment, net | 203,720 | 188,193 |
| Operating lease right-of-use assets | 394,435 | 206,801 |
| Investments | 48,704 | 78,565 |
| Intangible assets, net | 72,510 | 82,741 |
| Goodwill | — | 49,238 |
| Other non-current assets | 55,336 | 58,055 |
| Total assets | $1,377,449 | $1,665,342 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $14,169 | $9,323 |
| Deferred revenue (includes $795 and $5,426 from related parties) | 27,710 | 44,486 |
| Accrued expenses and other current liabilities | 65,387 | 110,051 |
| Total current liabilities | 107,266 | 163,860 |
| Non-current liabilities: | ||
| Deferred revenue, net of current portion (includes $72,260 and $119,053 from related parties) | 98,783 | 158,062 |
| Operating lease liabilities, non-current | 438,766 | 221,835 |
| Other non-current liabilities | 16,576 | 24,433 |
| Total liabilities | 661,391 | 568,190 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | — | — |
| Common stock, $0.0001 par value (Note 12) | 5 | 5 |
| Additional paid-in capital | 6,555,416 | 6,386,191 |
| Accumulated deficit | (5,837,557) | (5,290,528) |
| Accumulated other comprehensive (loss) income | (1,806) | 1,484 |
| Total stockholders’ equity | 716,058 | 1,097,152 |
| Total liabilities and stockholders’ equity | $1,377,449 | $1,665,342 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.